Sheena Jonathan sold $124K of NTRA

Sheena Jonathan sold 479 shares of Natera, Inc. (NTRA) at an average of $257.93 ($254.07–$260.49, $0.12M total) across 2 trades over 2026-07-27 to 2026-07-28 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Sheena Jonathan
Published Jul 30, 2026, 1:35 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 30, 2026, 2:01 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$NTRA
Neutral
high confidence
Mentioned
$NTRA
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NTRANeutralLow
01

Why it matters

The disclosure provides transparency on insider selling activity but does not include new operational or financial fundamentals for Natera.

02

Market read

For traders, the main actionable element is sentiment monitoring around insider activity; fundamental impact is likely limited absent other catalysts.

03

What to watch

Traders may over-weight insider sales; without accompanying guidance, trial, or financing news, the signal is usually weak.

Relevance 3/10Novelty 3/10Timing: after-hours filing disclosure on 2026-07-29 for sales executed 2026-07-27 to 2026-07-28

Background

The article is an SEC Form 4 insider transaction for Natera, Inc. reported by director Sheena Jonathan.

Company-level read

Ticker impact

$NTRANeutralHigh confidence
Context

Natera director Sheena Jonathan sold about $123.5K of NTRA shares via a 10b5-1 plan on 2026-07-27 to 2026-07-28.

Expected impact

Likely minimal price impact; any reaction should fade unless accompanied by other company-specific news.

Evidence & confidence

The filing is a Form 4 insider transaction, explicitly tied to a pre-arranged 10b5-1 plan, and the disclosed size is modest relative to typical large-cap trading flows.

Market effects

No direct sector read-through; this is company-specific insider trading disclosure.

None.

None.

Counterpoint

Because the sale is under a pre-arranged 10b5-1 plan, it may reflect scheduled liquidity needs rather than a change in outlook.

Key entities

  • Natera, Inc.

    Company whose director insider sale is disclosed on Form 4.

  • Sheena Jonathan

    Director who executed two open-market sales under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$NTRAMed

What's Next for Colorectal Cancer? A Major Announcement at OncoDaily

Natera announced a partnership with Agenus to use Signatera ctDNA testing in the Phase III ROBIN trial for colorectal cancer. The trial will compare neoadjuvant immunotherapy plus surgery to upfront surgery. Dr. Robert Lentz, Natera's Medical Director, highlighted the potential of ctDNA testing in treatment evaluation and decision-making.

$NTRAMed

Natera CFO Defends CEO Switch, Calls $6 Billion Revenue Target a “Way Station”

Natera CFO David Brophy defended the CEO transition and outlined long-term revenue targets. He estimated a $20B-$40B market opportunity for Signatera, with $1B revenue expected this year. Brophy also discussed competition, pricing, and market expansion into colorectal cancer screening and early detection tests. Natera (NASDAQ:NTRA) develops genetic testing and molecular diagnostics for various health applications.

$NTRAMed

Natera, Incyte Launch Phase 2 MRD-Guided Colorectal Cancer Study

Natera (NTRA) and Incyte (INCY) launched a Phase 2 study for colorectal cancer using Natera's Signatera test to identify high-risk patients. The trial will evaluate Incyte's INCA33890 immunotherapy in stage 2 or 3 patients post-treatment. Signatera will monitor patients for up to 12 months, with MRD-positive patients potentially enrolling. The study aims to improve outcomes by intervening earlier. NTRA closed at $320.39, up 3.13%.